Negative effect platypus
101. Effects of tubing degradation and pump position on extracorporeal circulation performance.
Schröter F, Müller T, Hartrumpf M, Ostovar R, Kühnel RU, Albes JM
Artificial organs, 2020
102. Exploring patient-physician trust dynamics in patients with psychocutaneous and general dermatological disease.
Stavrou PZ, Gkini MA, Taylor R, Bewley A
The British journal of dermatology, 2020
103. Platinum-containing regimens for triple-negative metastatic breast cancer.
Egger SJ, Chan MMK, Luo Q, Wilcken N
The Cochrane database of systematic reviews Cochrane Database Syst Rev Platinum-containing regimens for triple-negative metastatic breast cancer. CD013750 10.1002/14651858.CD013750 In a previous Cochrane Review, we found that for women with metastatic breast cancer unselected for triple-negative disease, there is little or no survival benefit and excess toxicity from platinum-based regimens. In subgroup analyses, however, we found preliminary low-quality evidence of a survival benefit from platinum-based regimens for women with metastatic triple-negative breast cancer (mTNBC). This review updates the evidence from the mTNBC subgroup analyses in the previous Cochrane Review. To assess the effects of platinum-containing chemotherapy regimens with regimens not containing platinum in the management of women with mTNBC. We obtained relevant studies published prior to 2015 and their extracted results from the mTNBC subgroup analysis in the previous Cochrane Review. We searched the Cochrane Breast Cancer Group's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov between 2015 and 27 September 2019. We identified further potentially relevant studies from previous trial reports, systematic reviews, and meta-analyses. Randomised trials comparing platinum-containing chemotherapy regimens with regimens not containing platinum in women with mTNBC. Individual trials could compare one or more platinum-based regimens to one or more non-platinum regimens; hence there could be more 'treatment-comparisons' (i.e. platinum regimen versus non-platinum regimen comparison) than trials. Trial participants may have been purposely selected for mTNBC or inadvertently selected as a subgroup. At least two independent reviewers assessed studies for eligibility and quality, and extracted all relevant data from each study. We derived hazard ratios (HRs) for time-to-event outcomes, where possible, and used fixed-effect models for meta-analyses. We analysed objective tumour response rates (OTRRs) and toxicities as binary (dichotomous) outcomes with risk ratios (RRs) used as measures of effects. We extracted quality of life data, if available. We used GRADE to rate the quality of evidence for time-to-event and tumour response outcomes. This review includes 13 treatment-comparisons involving 1349 women from 10 studies. Twelve of the 13 treatment-comparisons were included in one or more meta-analyses. Of the 13 treatment-comparisons, six and eight had published or provided time-to-event data on overall survival (OS) or progression-free survival/time to progression (PFS/TTP), respectively, that could be included in meta-analyses. Ten treatment-comparisons published or provided OTRR data that could be included in meta-analyses. Eight of the 13 treatment-comparisons were from studies that selected participants on the basis of mTNBC status, while the other five treatment-comparisons were from studies that reported mTNBC results as part of subgroup analyses. Analysis of six treatment-comparisons indicated that platinum-containing regimens may have provided a small survival benefit to mTNBC patients (HR 0.85, 95% CI 0.73 to 1.00; 958 women; moderate-quality evidence) with no evidence of heterogeneity (P = 0.41; I2 = 1%). Data from eight treatment-comparisons showed that platinum regimens may improve PFS/TTP (HR 0.77, 95% CI 0.68 to 0.88; 1077 women; very low-quality evidence). There was marked evidence of heterogeneity (P < 0.0001; I2 = 80%). There was also low-quality evidence of better tumour response for platinum recipients (RR 1.40, 95% CI 1.22 to 1.59; 1205 women) with some evidence of heterogeneity (P = 0.01; I2 = 58%). The observed heterogeneity for the PFS/TTP and OTRR outcomes may reflect between-study differences and general difficulties in assessing tumour response, as well as the varying potencies of the comparators. Compared with women receiving non-platinum regimens: rates of grade 3 and 4 nausea/vomiting were higher for platinum recipients (RR 4.77, 95% CI 1.93 to 11.81; 655 women; low-quality evidence) and rates of grade 3 and 4 anaemia were higher for platinum recipients (RR 3.80, 95% CI 2.25 to 6.42; 843 women; low-quality evidence). In general, however, relatively few intervention-comparisons could be included in meta-analyses for adverse events. None of the studies reported quality of life. For women with mTNBC, there was moderate-quality evidence of a small survival benefit from platinum-based regimens compared to non-platinum regimens. This finding is consistent with findings of a PFS/TTP benefit and improved tumour response from platinum-based regimens. These potential benefits, however, should be weighed against previously identified excess toxicities from platinum-based regimens, particularly regimens containing cisplatin. Further randomised trials of platinum-based regimens among women with mTNBC are required. Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Egger Sam J SJ Cancer Research Division, Cancer Council NSW, Sydney, Australia. Chan Matthew Ming Ki MMK Department of Medical Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford, Australia. Luo Qingwei Q Cancer Research Division, Cancer Council NSW, Sydney, Australia. Wilcken Nicholas N Medical Oncology, Crown Princess Mary Cancer Centre, Westmead, Australia. Sydney Medical School, The University of Sydney, Sydney, Australia. eng ClinicalTrials.gov NCT00201760 NCT01149083 NCT00717951 NCT01898117 NCT02207335 NCT02207361 Journal Article Review 2020 10 21 England Cochrane Database Syst Rev 100909747 1361-6137 IM 2020 10 21 6 7 2020 10 22 6 0 2020 10 22 6 0 epublish 33084020 10.1002/14651858.CD013750 References, 2020
104. Spatial-temporal analysis of net primary production (NPP) and its relationship with climatic factors in Iran.
Kamali A, Khosravi M, Hamidianpour M
Environmental monitoring and assessment, 2020
105. Bloodstream infection due to Herbaspirillum sp.: case series and review of literature.
Bloise I, Guedez-López GV, Tejedor-Rodríguez M, Romero-Gómez MP, García-Rodríguez J, Mingorance J, Cendejas-Bueno E
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020
106. Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer.
Lovejoy LA, Rummel SK, Turner CE, Shriver CD, Ellsworth RE
Familial cancer, 2020
107. Hemodynamic findings in normotensive women with small for gestational age and growth restricted fetuses.
Di Pasquo E, Ghi T, Dall'Asta A, Angeli L, Ciavarella S, Armano G, Sesenna V, Di Peri A, Frusca T
Acta obstetricia et gynecologica Scandinavica, 2020
108. Diagnostic accuracy of SPECT and PET myocardial perfusion imaging in patients with left bundle branch block or ventricular-paced rhythm.
Vidula MK, Wiener P, Selvaraj S, Khan MS, Salam UA, Rojulpote C, Metzler SD, Denduluri S, Guerraty M, Julien H, Bravo PE
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2020
109. Sex-based differences in time to surgical care among pancreatic cancer patients: A national study of Medicare beneficiaries.
Azap RA, Hyer JM, Diaz A, Tsilimigras DI, Mirdad RS, Pawlik TM
Journal of surgical oncology J Surg Oncol Sex-based differences in time to surgical care among pancreatic cancer patients: A national study of Medicare beneficiaries. 10.1002/jso.26266 The objective of this study was to characterize time from cancer symptoms to diagnosis and time from diagnosis to surgical treatment among patients undergoing pancreatectomy for cancer. Medicare beneficiaries who underwent pancreatectomy for cancer between 2013 and 2017 were identified using the 100% Medicare Inpatient Standard Analytic Files. Mixed effects negative binomial regression models were utilized to determine which factors were associated with the number of weeks to diagnosis and pancreatic resection. Among 7647 Medicare beneficiaries, two-thirds (n?=?5127, 67%) had symptoms associated with a pancreatic cancer diagnosis before surgery. Median time from the first symptom to diagnosis was 6?weeks (IQR: 1-25) and the median time from diagnosis to surgery was 4?weeks (IQR: 2-15). In risk-adjusted models, female patients had 13% longer waiting times from identification of a related symptom to pancreatic cancer diagnosis (OR?=?1.13, 95% CI: 1.05-1.21) and 12% longer waiting times from diagnosis to surgery (OR?=?1.12, 95% CI: 1.07-1.18). Older age was associated with 10% longer waiting times from symptom identification to diagnosis (p?<?.0001). Female and older patients had longer wait times between symptom presentation and pancreatic cancer diagnosis. Sex-based disparities in cancer care need to be recognized and addressed by policymakers and health care institutions. © 2020 Wiley Periodicals LLC. Azap Rosevine A RA Department of Surgery, The Ohio State University, Wexner Medical Center, James Comprehensive Cancer Center, Columbus, Ohio, USA. Hyer James M JM Department of Surgery, The Ohio State University, Wexner Medical Center, James Comprehensive Cancer Center, Columbus, Ohio, USA. Diaz Adrian A National Clinician Scholars Program, Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA. Tsilimigras Diamantis I DI https://orcid.org/0000-0002-3676-9263 Department of Surgery, The Ohio State University, Wexner Medical Center, James Comprehensive Cancer Center, Columbus, Ohio, USA. Mirdad Rayyan S RS Department of Surgery, The Ohio State University, Wexner Medical Center, James Comprehensive Cancer Center, Columbus, Ohio, USA. Pawlik Timothy M TM https://orcid.org/0000-0002-7994-9870 Department of Surgery, The Ohio State University, Wexner Medical Center, James Comprehensive Cancer Center, Columbus, Ohio, USA. eng Journal Article 2020 10 20 United States J Surg Oncol 0222643 0022-4790 IM diagnosis disparities pancreatic cancer sex wait time 2020 09 06 2020 10 01 2020 10 05 2020 10 21 6 7 2020 10 22 6 0 2020 10 22 6 0 aheadofprint 33084065 10.1002/jso.26266 REFERENCES, 2020
110. Responses of plant biomass and yield component in rice, wheat, and maize to climatic warming: a meta-analysis.
Liu X, Ma Q, Yu H, Li Y, Zhou L, He Q, Xu Z, Zhou G